The United States federal government is updating its Schedule 1 controlled substance definitions to specifically target and ban synthetic kratom derivatives. This regulatory move seeks to eliminate high-potency lab-created versions of the substance while maintaining legal access to natural kratom products.
The Federal Shift to Ban Synthetic 7-OH Derivatives
The federal government's decision to revise Schedule 1 definitions focuses on the danger of synthetic kratom, which often contains concentrations of 7-hydroxymitragynine (7-OH) far exceeding those found in nature . In natural kratom, 7-OH typically accounts for only about 2% of the total alkaloid content, but synthetic versions amplify this compound to increase potency. According to the report, this move is intended to curb the proliferation of dangerous derivatives that mimic the effects of classic opioids.
This targeted regulation reflects a growing consensus between critics and proponents. Mac Harrow, a senior fellow on public policy for the American Kratom Association, told Gizmodo that his organization fully supports the scheduling of these synthetics. By isolating the synthetic derivatives, the government aims to reduce the risk of fatal overdoses associated with concentrated products often sold in gummies, drinks, and tablets.
The 100,000 Children and the Rise of Synthetic Overdoses
The urgency of this regulatory shift is underscored by alarming usage data and recent fatalities. Research from the University of Michigan conducted in May revealed that approximately five million Americans have tried kratom at least once, a figure that includes more than 100,000 children between the ages of 12 and 17.. As reported by the source, current active users are estimated at 1.7 million people aged 12 and older.
The danger is most acute in the unregulated retail market. Sean McCabe, director of the Center for the Study of Drugs, Alcohol, Smoking and Health at the University of Michigan , noted that synthetic 7-OH products are frequently sold at smoke shops and gas stations. these products can lead to severe addiction, with some users spending $200 to $300 daily. The human cost is already evident: at least six people died in connection with synthetic kratom last year, and two University of Mississippi students recently died after using these products, leading to federal prosecutions.
A Pivot from the DEA's Failed 2016 Ban Attempt
This new approach marks a significant strategic departure for federal law enforcement.. In 2016, the Drug Enforcement Administration (DEA) attempted to list kratom and its primary alkaloids as Schedule I substances, which would have effectively criminalized the plant entirely. That effort was abandoned after intense pushback from advocates and users who argued the plant could be used safely for chronic pain or as a tool for opioid replacement therapy.
The current proposal is rooted in more nuance, acknowledging that mitragynine and 7-OH act as partial agonists of the mu-opioid receptor. Proponents argue this allows users to manage substance use disorders without the life-threatening respiratory depression associated with morphine or oxycodone. By focusing on synthetics rather than the plant, the DEA is attempting to balance public safety with the needs of those using natural kratom as a harm-reduction tool.
The Conflict Between the FDA's Stance and 1.7 Million Users
Despite the move toward a middle ground, a significant gap remains between user experience and federal medical guidance. The May University of Michigan study found that roughly 53% of recent kratom users reported having a substance use disorder within the past year. While users view the plant as a lifeline, Sean McCabe emphasized that the FDA has not approved kratom as a safe or effective treatment for any medical condition.
Several critical questions remain unanswered by the curret federal plan. Specifically, it is unclear how the government intends to enforce these definitions at the retail level to ensure that "natural" products in smoke shops are not actually synthetic blends. Furthermore, the report does not specify what new labeling requirements, if any, will be mandated to help consumers distinguish between the legal plant and the now-illegal synthetic derivatives.
Comments 0